Clinical Research

Division of Clinical Research

The Clinical Research Division in the Department of Dermatology conducts ongoing studies of novel therapeutic agents. Established to explore new drugs, devices, and therapies, the Clinical Research Division is dedicated to pioneering innovative breakthroughs in the field of dermatology.

Housed within the Department of Dermatology, the Clinical Research Division has ample office space and a fully equipped lab dedicated to tissue acquisition and analysis, laser scanning confocal microscopy, and more.

CTCL:

“Phase IV Randomized Study of Two Dose Levels of Targretin Capsules in Patients with Refractory Cutaneous T-Cell Lymphoma”

For additional information please follow this link: http://clinicaltrials.gov/ct2/show/NCT01007448

Alopecia Areata:

“Safety and Efficacy of Combined Restylane and Intralesional Triamcinolone Acetonide 10 mg/mL in Patients with Alopecia Areata”

“Alopecia Areata Registry and Immunogenetic Mechanisms”

For additional information please follow this link: http://clinicaltrials.gov/ct2/show/NCT00177073

Psoriasis:

“Safety and Efficacy of Botulimum Toxin Injections in the Treatment of Psoriasis Vulgaris”

For additional information please follow this link:  http://clinicaltrials.gov/ct2/show/NCT00816517

“A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of 2 Oral Doses of CP-690,550 in Subjects with Moderate to Severe Chronic Plaque Psoriasis”

For additional information please follow this link: http://clinicaltrials.gov/ct2/show/NCT01241591

Atopic Dermatitis (Pediatric):

“APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis”

For additional information please follow this link: http://clinicaltrials.gov/ct2/show/NCT00475605

Discoid Lupus Erythematosus:

“A Phase 2, Pilot, Multicenter, Randomized, Placebocontrolled, Sequential, Ascending Dose Study To Characterize The Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Activity Of CC-930 In Subjects With Recalcitrant Discoid Lupus Erythematosus (DLE)”

For additional information please follow this link: http://clinicaltrials.gov/ct2/show/NCT01466725

Healthy Participants (Controls):

“Nerve Function in Skin Diseases”

“Cutaneous Innervation in Skin Diseases”

For more information, contact:
Kathleen Kane, CCRC

krkane@umn.edu 
Phone number: 612-624-5721

Intent to Submit Form